Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 12/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.46 |
| ▸ | PDE4A | P27815 | 7/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6384297 | 0.93 | PDE4D (0.45) | PDE4DPDE4BPDE4APDE4CCYP2D6 | |
| SCHEMBL3470159 | 0.93 | PDE4D (0.45) | PDE4DPDE4BPDE4APDE4CCYP2D6 | |
| SCHEMBL3471184 | 0.93 | PDE4D (0.49) | PDE4DPDE4BPDE4APDE4CCYP2D6 | |
| Hydrochloric Acid SCHEMBL3470610 | 0.92 | PDE4D (0.48) | PDE4DPDE4BPDE4APDE4CCYP2D6 | |
| SCHEMBL5481129 | 0.92 | PDE4D (0.39) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5477358 | 0.89 | PDE4B (0.49) | PDE4DPDE4BPDE4APDE4CCYP2D6 | |
| SCHEMBL5482662 | 0.88 | PDE4D (0.57) | PDE4DPDE4BPDE4APDE4CCHEK1 | |
| SCHEMBL2346489 | 0.87 | PDE4D (0.39) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2345712 | 0.87 | PDE4D (0.39) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2343649 | 0.86 | PDE4D (0.38) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539164-A1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-15 | — | — | EP | claimed |
| WO-2004019944-A1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | claimed |
| EP-1720835-B1 | NOVEL GUANIDINYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AS EFFECTIVE PHOSPHODIESTERASE (PDE) 4 INHIBITORS | NYCOMED GMBH (DE) | 2012-12-12 | — | — | EP | disclosed |
| US-8329906-B2 | Guanidinyl-substituted hydroxy-6-phenylphenanthridines | NYCOMED GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20100035913-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (PDE) 4 inhibitors | NYCOMED GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-7585872-B2 | Guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (PDE) 4 inhibitors | NYCOMED GMBH (DE) | 2009-09-08 | — | — | US | disclosed |
| US-20070167482-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors | ALTANA PHARMA AG (DE) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167482-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors | PDE4A, PDE3A, PDE4B | PDE4D 8/4885PDE4B 3/4885PDE4A 1/4885 |
| US-20100035913-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (PDE) 4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4D 5/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.